BMS and Johnson & Johnson are engaged in a legal battle over their respective CAR-T cell therapies for multiple myeloma in Europe. BMS, through its acquired subsidiary 2seventy bio, has filed a patent infringement lawsuit at the UPC against Johnson & Johnson and Legend Biotech concerning their drug Carvykti. Concurrently, Johnson & Johnson is challenging the patent at the UK High Court and the European Patent Office.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
BMS and Johnson & Johnson battle over novel CAR-T cell therapy in Europe
BMS and Johnson & Johnson are engaged in a legal battle over their respective CAR-T cell therapies for multiple myeloma in Europe. BMS, through its acquired subsidiary 2seventy bio, has filed a patent infringement lawsuit at the UPC against Johnson & Johnson and Legend Biotech concerning their drug Carvykti. Concurrently, Johnson & Johnson is challenging the patent at the UK High Court and the European Patent Office.